Summary
CVS Health Corporation (CVS) has filed an 8-K report on October 16, 2023, detailing a significant change in its executive leadership. Effective October 13, 2023, Executive Vice President and Chief Financial Officer Shawn M. Guertin has begun an unexpected personal leave of absence due to unforeseen family medical reasons. This transition has led to the appointment of Thomas F. Cowhey, Senior Vice President of Corporate Finance, as the Interim Chief Financial Officer. Mr. Cowhey brings substantial financial experience from previous roles at Surgery Partners and Aetna, as well as investment banking experience at Credit Suisse. Despite this executive change, CVS Health has reaffirmed its previously issued full-year 2023 financial guidance. The company continues to project GAAP diluted earnings per share (EPS) to be in the range of $6.53 to $6.75 and Adjusted EPS to be between $8.50 to $8.70. This reaffirmation suggests management's confidence in the ongoing operational performance and strategic execution of the company, even amidst the unexpected departure of its CFO.
Key Highlights
- 1CFO Shawn M. Guertin has commenced a personal leave of absence for family medical reasons, effective October 13, 2023.
- 2Thomas F. Cowhey, Senior Vice President of Corporate Finance, has been appointed as Interim Chief Financial Officer.
- 3Mr. Cowhey has a strong financial background, including previous CFO experience at Surgery Partners and roles at Aetna and Credit Suisse.
- 4CVS Health has reaffirmed its full-year 2023 GAAP diluted EPS guidance of $6.53 to $6.75.
- 5The company has also reaffirmed its full-year 2023 Adjusted EPS guidance of $8.50 to $8.70.
- 6The reaffirmation of guidance indicates continued confidence in the company's financial outlook despite the CFO transition.